Skip to main content
. 2021 Dec 8;97(2):260–262. doi: 10.1016/j.abd.2021.02.009

Table 1.

Comparison of selected features of three unusual FFA subtypes.

Atypical FFA pattern Male pattern Plaque pattern Ophiasic pattern p value
Total
n = 12 (100.0%) n = 7 (100.0%) n = 8 (100.0%) Male × Plaque Male × Ophiasic Plaque × Ophiasic Overall n = 27 (100%)
Age: mean (SD) 65.3 (7.3) 60.7 (8.9)a 64.4 (14.4) 0.260 0.831 0.508 0.693 63.9 (10.0)b
Fitzpatrick II–III phototypec: n (%) 6 (50.0) 4 (57.1) 1 (12.5) 0.764 0.085 0.067 0.133 11 (40.7)
Approximate progression (cm/year): mean (SD) 1.02 (1.07)d 0.67 (0.51)e 2.25 (1.22)f 0.581 0.026i 0.038i 0.026i 1.31 (1.18)g
Stability: n (%) 8 (66.7) 4 (57.1) 1 (12.5) 0.678 0.017i 0.067 0.054 13 (48.1)
Disease duration until stabilization (months):mean (SD) 27.0 (16.0)h 18.8 (6.7)h 36 (0)h 0.503 0.474 25.2 (13.6)h
Disease evolution (years): mean (SD) 6.7 (5.3) 7.5 (6.4)a 6.7 (3.4)a 0.564 0.931 0.640 0.944 6.9 (5.0)
Facial papules: n (%) 4 (33.3) 0 (0.0) 2 (25.0) 0.086 0.690 0.155 0.284 6 (22.2)
Lichen planus pigmentosus: n (%) 3 (25.0) 0 (0.0) 3 (37.5) 0.149 0.550 0.070 0.240 6 (22.2)
Eyebrow alopecia: n (%) 11 (91.7) 0 (0.0) 7 (87.5) <0.001i 0.761 <0.001i <0.001i 18 (66.7)
Comorbidities: n (%)
Systemic arterial hypertension 6 (50.0) 6 (85.7) 6 (75.0) 0.120 0.264 0.605 0.281 18 (66.7)
Diabetes mellitus 2 (16.7) 3 (42.9) 3 (37.5) 0.211 0.292 0.833 0.346 8 (29.6)
Dyslipidemia 4 (33.3) 2 (28.6) 2 (25.0) 0.830 0.690 0.876 0.935 8 (29.6)
Hypothyroidism 3 (25.0) 2 (28.6) 1 (12.5) 0.865 0.494 0.438 0.661 7 (25.9)

Notes: 2 × 2 comparisons of continuous variables were carried out using Student's t test for independent samples; 3 × 2 comparisons of continuous variables used the Analysis of Variance (ANOVA) table; percentage comparisons used Fisher's exact test; SD, Standard Deviation.

a

n = 6.

b

n = 26.

c

in comparison with Fitzpatrick phototype IV–VI.

d

n = 11.

e

n = 5.

f

n = 7.

g

n = 15.

h

only for patients who reported stability; Stata 12.0/SE for Mac was used.

i

p < 0.05; the approximate progression for those without full follow-up was estimated as a direct proportion of the presumed one-year progression.